How corruption, competition challenge big pharma in China
This article was originally published in Scrip
Executive Summary
Further bribery investigations and details of wrongdoing can be expected in the Chinese drug market, as the country's administration pursues its anti-corruption policy. Experts believe that the pharma industry will continue to be a prime target for investigation, suggesting that reputationally harmful news will carry on blighting drug companies for quite some time.